The latest biotech news

News and Trends 28 Feb 2023

GC Biopharma acquiring hemophilia rare disease pipeline

GC Biopharma Corp., a South Korean provider of biopharmaceutical products, has signed an asset purchase agreement with Catalyst Biosciences to acquire three programs related to the orphan hematology disorders. The agreement includes Marzeptacog alfa (MarzAA), an engineered factor VIIa, which is ready for phase 3 clinical stage development. In its previous clinical development trials, MarzAA […]

February 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 24 Feb 2023

Resalis Therapeutics receives €10M to develop obesity and NAFLD treatment

Resalis Therapeutics has completed a seed financing round of €10 million to establish a non-coding RNA (ncRNA)-based therapeutic approach for the treatment of metabolic diseases. The funding will support the finalization of IND-enabling studies for the Resalis Therapeutics’ lead program, RES-010, which Resalis will initially develop as a novel treatment for obesity and nonalcoholic fatty […]

February 24, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 24 Feb 2023

Beyond Biotech podcast 35: Rare Disease Day

As February 28 is Rare Disease Day, we have three guests on the podcast today all relevant to rare diseases. And they are Dan Mandell, CEO and co-founder of GRO Biosciences; Stefano Portolano, chief executive officer, Azafaros; and from Replay, Adrian Woolfson, executive chairman, president, and co-founder, and Lachlan MacKinnon, CEO and co-founder. Rare Disease […]

February 24, 2023

News and Trends 24 Feb 2023

AELIX announces ‘important step towards HIV eradication’

AELIX Therapeutics S.L., a clinical-stage biotechnology company specializing in the discovery and development of immunotherapies for HIV infection, has announced positive topline results from its AELIX-003 trial. The study evaluated the safety, tolerability, immunogenicity and efficacy of AELIX Therapeutics’ HTI T-cell therapeutic HIV vaccine in combination with Gilead’s investigational Toll-Like Receptor 7 (TLR7) agonist, vesatolimod […]

February 24, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 24 Feb 2023

Sanofi hemophilia drug gets FDA approval

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy. ALTUVIIIO is indicated for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as perioperative management (surgery) for adults and children with hemophilia […]

February 24, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 24 Feb 2023

Researchers discover how tumor cells become resistant to colorectal cancer chemotherapy

Platinum-based chemotherapy, which is used to treat advanced colorectal cancer, accumulates in the healthy cells surrounding the cancer cells and, as a result, can reduce tumor sensitivity to treatment. This is demonstrated by a study published in the journal Nature Communications by the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar), in collaboration with […]

February 24, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Depression trial gets green light

Beckley Psytech Ltd has received investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA) for a global multi-site phase IIb study exploring the safety, efficacy and tolerability of two doses of its lead compound, BPL–003, in patients with treatment resistant depression (TRD). BPL-003 is the Beckley Psytech’s novel synthetic formulation of […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Positive topline data from sepsis trial

Modus Therapeutics AB has published positive top-line data from its phase 1b lipopolysaccharide (LPS) provocation study, a key step in evaluating the potential of its lead asset, sevuparin, as a treatment for sepsis and other conditions with systemic inflammation. In the study, healthy volunteers received LPS to induce a transient systemic inflammation reaction together with […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

New promising targeted drug for a rare leukemia

Targeted drugs have been developed to supplement chemotherapy in the treatment of cancer. These drugs only affect cancer cells, leaving healthy cells alone. Venetoclax is a new targeted therapy option for the treatment of acute myeloid leukemia (AML). It was recently granted marketing authorization in Finland. Venetoclax works by sensitizing cancer cells to programmed cell […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Sherlock obtains Cas12 CRISPR patent

Sherlock Biosciences, a company engineering biology to bring next-generation lab-quality diagnostic testing to the point of need, has announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent for the diagnostic use of the Cas12 enzyme. Sherlock Biosciences has exclusive U.S. rights to the patent from Shanghai-based Tolo Biotech, plus additional intellectual […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Italian life sciences fund hits €175M

Panakès Partners, an Italian venture capital firm in the life sciences sector, has closed its Purple Fund with a total of €175 million ($185.4 million). Panakès Purple Fund is currently the largest Italian Venture Capital Fund, in the investment phase, dedicated to life sciences, with an investment focus in Italy and Europe, as well as […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

Moderna and Life Edit Therapeutics look to speed up gene editing therapies

Moderna, Inc., a biotechnology company working on messenger RNA (mRNA) therapeutics and vaccines, and Life Edit Therapeutics Inc., an ElevateBio company focused on gene editing technologies and therapeutics, have announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit’s suite of proprietary […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

GC Biopharma acquiring hemophilia rare disease pipeline

Resalis Therapeutics receives €10M to develop obesity and NAFLD treatment

Beyond Biotech podcast 35: Rare Disease Day

AELIX announces ‘important step towards HIV eradication’

Sanofi hemophilia drug gets FDA approval

Researchers discover how tumor cells become resistant to colorectal cancer chemotherapy

Depression trial gets green light

Positive topline data from sepsis trial

New promising targeted drug for a rare leukemia

Sherlock obtains Cas12 CRISPR patent

Italian life sciences fund hits €175M

Moderna and Life Edit Therapeutics look to speed up gene editing therapies

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!